Equity Research, Broker Reports, and media content on Consort Medical

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Consort Medical
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
  • 21 Oct 19
Quarterly Research Outlook Autumn 2019

Following continued delays of a Brexit agreement, few sectors within the UK market have remained attractive to investors despite low valuations. One sector which has continued to outperform despite the political drama has been the UK video gaming sector (henceforth UK gaming), which we are fans of. We believe a combination of sector-leading growth, strong cash conversion and timely cyclical positioning support our positive view on the UK video gaming sector.

Companies: ABBY AMS ANX ARS ATYM AVON BLVN PIER BUR CGS CAML CSRT TIDE CYAN JET2 DEMG ELM EMR FPO FDEV GTLY GENL GHH GRI GEEC GKP HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG KAPE KEYS KWS KCT KGH LAM LIT LOK MACF MANO MOD OXIG PCA PANR APP SRE PHC HBR RBW RMM RBGP RSW RNO ROR SUS SCPA SEN SHG SOLG SOM SUMO TM17 INCE TWD TRAK TRI VNET VTC ZOO ZTF REDD

  • 23 Jul 19
Quarterly Research Outlook - Summer 2019

In January, we provided a list of 11 stocks for 2019 that we believed would perform strongly with attractive catalysts that could lead to material outperformance. In this Quarterly Research Outlook, we revisit these views, analysing what has happened and how the remaining six months of the year could play out.

Companies: AMS ANX ARS ATYM AVON BLVN PIER BUR CGS CAML CALL CSRT TIDE CYAN JET2 DEMG ELM EMR FPO FST GTLY GENL GRI GEEC GKP HMI HAYD HEAD HILS HTG HUR HYR IBPO IOG INDI JHD JOG KAPE KEYS KCT KGH LAM LIT LOK MACF MANO PCA PANR PXC PHC HBR RBW RMM RSW RNO RKH RBGP ROR SUS SCPA SHG SOLG SOM TWD TRAK TSG TRI VNET VTC ZOO ZTF REDD

  • 11 Apr 19
Quarterly Research Outlook

We’re just over three months in to 2019 and we’ve seen a 10% UK market rally, retracing much of the Q4 decline, such is the nature of fickle market sentiment. That said, many of the issues we wrote about three months ago that were impacting markets remain: notably Brexit, trade wars, geopolitics and global monetary policy. The 2019 rally thus far feels somewhat fragile, with competing forces of optimism on a potential trade deal which could underpin the rally, against the deterioration in underl

Companies: ARS CYAN HYR LIT SOM ABBY AMS AMER ANX ATYM AVON BLVN PIER BUR CGS CAML CALL CSRT TIDE JET2 DEMG EMR FPO FST GTLY GENL INCE GRI GEEC HDY HMI HAYD HEAD HILS HTG HUR IBPO INDI JHD JOG KEYS KCT KGH LAM LOK MACF CRDL MANO MOD MKLW OXIG PCA PANR APP PXC PHC HBR RBW RMM RSW RNO RKH RBGP ROR SUS SCPA SHG SOLG TRAK TRI VNET VTC ZOO ZTF REDD

  • 01 Feb 19
Most popular equity research this week | 28 Jan - 1 Feb

See what's trending this week...

Companies: MODWJAARSATYM21WALHVSAVONCSRTCGSTIDEELMFPOHEADHILSHTGAMSMACFMKLWOXIGAPPSCPARSWRNOSUSKCTTRIVTCIQEZTFDEMGEMRBLVNGRIRMMHDYSHGRKHJHDTRAKSOLGVNETJET2LAMZOOHBRCALLHURCAMLANXIOGPCARBGPKGHTWDPIERHAYDFLO7DIGSPERORGTLYW7LJOGPRSMKEYSINDIIBPORBWABBYGENLFSTGEEC
  • 31 Jan 19
Quarterly Research Outlook

The market has not faced quite so many conflicting challenges for a number of years, whether related to global geopolitics, trade wars, ongoing Eurozone issues or the “will they, won’t they” saga of Brexit. In our Best Ideas, we sought to highlight stocks that present investors with interesting opportunities following recent market moves. Those stocks, we believe, warrant investor attention, in many cases for uncorrelated or stockspecific reasons, regardless of the near-to-medium term market dir

Companies: 7DIG ABBY AMS ANX ARS ATYM AVON BLVN PIER CGS CAML CALL CSRT TIDE JET2 DEMG ELM EMR FPO FST GTLY GENL GRI GEEC HDY HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG KEYS KCT KGH LAM MACF MOD MKLW OXIG PCA APP HBR RBW RMM RSW RNO RKH RBGP ROR SUS SCPA SHG SOLG TWD TRAK TRI VNET VTC ZTF REDD

  • 03 Nov 18
Most popular equity research this week | 22 Oct - 2 Nov

See what's trending this week...

Companies: HMIARSATYM21WAVONCSRTCGSTIDEELMFPOHEADHILSHTGAMSMACFMKLWOXIGAPPSCPARSWRNOSUSTRIVTCZTFDISWMHAMERFPMDEMGEMRBLVNGRIRMMHDYCKTSHGSXXRKHJHDTRAKSOLGPHDVNETJET2LAMPDGCALLHURCAMLAREANXIOGPCARBGPKGHTWDPIERHAYDCAKENAH7DIGRORGTLYW7LJOGCRDLKEYSGYGINDIIBPORBWABBYFLTRENTGENLSFEFSTGEEC
  • 23 Oct 18
Quarterly Research Outlook

The June IPO of Knights Group Holdings, a Top-100 regional law firm, marked the fifth entrant to the burgeoning UK-listed legal sector. Following recent expansion of our coverage across all five listed legal firms, complemented by coverage of three broader support services peers with exposure to the sector, we revisit and build upon our views on this rapidly evolving sector.

Companies: ARS GTLY GENL KEYS KGH CRDL RBGP TWD 7DIG ABBY AMS AMER ANX ATYM AVON BLVN PIER CGS CAML CALL CSRT TIDE JET2 DEMG ELM EMR FPM FPO FST GRI GEEC HDY HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG LAM MACF MKLW NAH OXIG PCA APP CAKE PDG RBW RMM RSW RNO RKH ROR SUS SCPA SHG SOLG TRAK TRI VNET VTC ZTF REDD

  • 20 Jul 18
Most popular equity research this week | 16 - 20 July

See what's trending this week...

Companies: HMI21WAPCAVONCSRTCGSTIDEELMFPOHEADHILSHTGAMSMACFMPACMKLWOXIGAPPSNXSCPARSWRNOSUSKCTTRIVTCZTFFPMDEMGAFRNEMRBLVNHDYBGOSHGRKHJHDTRAKJET2LAMPDGCALLHURIOGPCAEUSPCDMGETBPIERLSAIHAYDFDMCAKENAHSPERORGTLYECSCFUTRINCEINDIIBPORBWABBYKETLJELGENLAXUGEEC
  • 18 Jul 18
Quarterly Research Outlook

In Q2, UK equities regained some of their poise after the draw down in Q1, although uncertainty around Brexit continued to grab the headlines. On the back of this, investor concern about the UK economy has been understandable in recent months given a number of negative data points. However, we see reasons for optimism for UK Plc with wage growth supporting an improving outlook for the consumer and business investment holding up. That said, continuing UK political disruption clearly remains a ris

Companies: AMER EMR HMI JOG PDG ABBY AMS AVON BLVN PIER CGS CALL CSRT TIDE JET2 DEMG ELM FPM FPO GTLY GENL INCE GEEC HDY HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD LAM MACF MKLW NAH OXIG PCA APP CAKE RBW RSW RNO RKH ROR SUS SCPA SHG KCT TRAK TRI VTC ZTF REDD

  • 14 Jun 18
Morning Song

1Spatial (SPA LN) Capital markets day highlights growth potential | Abzena (ABZA LN) Monetising the Abzena Inside portfolio | Consort Medical (CSRT LN) Prelims in line – another setback with Mylan | Gym Group (GYM LN) Positive corporate and premium pricing newsflow | N Brown Group (BWNG LN) In line update but number of moving parts might leave investors cold | Rathbone Brothers (RAT LN) Acquisition of Speirs & Jeffrey, no EPS accretion until FY20e | RhythmOne (RTHM LN) FY18 results show executio

Companies: ABZA CSRT GYM BWNG RAT RTHM SDY SPA

  • 07 Mar 18
Structural growth in a complex landscape

Pharmaceutical Services is a vast and varied landscape, reflecting the complexities in the discovery, development, manufacturing and monitoring of drugs and devices, all within a stringent regulatory environment. The overall growth prospects are highly favourable: drug development activity globally is on the up, led by smaller companies, which is driving demand for outsourced services. In this report we provide a breakdown of the sector into its main activity segments, and identify biologics, in

Companies: ABZA BQE CSRT INS UDG CLIN ERGO OXB

  • 05 Dec 17
N+1 Singer - Consort Medical - In line interims, still waiting for a catalyst

Interims are in line. Revenues +6.1% reported, PBT+7.7% but adj EPS was only up 3.2% and Net Debt is still high at £97.1m. There is no new news on Mylan contract for generic Advair and we do not expect to hear anything until mid-2018. A couple of small contracts have drifted away. We make only minor changes to our estimates and don’t see any catalysts in the short term. The shares now trading on 17.7x P/E to Apr-18, 12.4x EV/EBITDA - not obviously cheap without growth picking up but maybe there

Companies: Consort Medical
  • 20 Oct 17
Most popular equity research this week | 16 - 20 Oct

See what's trending this week...

Companies: WJASEEPLIFARNCSRTBTGAMSPHTMSYMDPHLGTEKFANCRRGDIMMAGYTSTLCTHBOTBDOTDVERBVXPSCLPABCFULDNLVLGHZDVECMTPHSHOECAKEC4XDSCSIDPRBGFISHHOTCJOULHCMMXCT
  • 10 Aug 17
Most popular equity research this week | 7 - 11 Aug

See what was trending this week...

Companies: PLISQSFARNCSRTBTGCTOAMSLGENSNXSUSDPHFA/EKFANCRIMMAGYCTHVERSPHRSCLPABCCNEKWSNAPSDNLBBSNEUSPVLGHZDMTPHFDMC4XDECSCPLUSTRMRHCMMXCTPPIXQRT
  • 15 Jun 17
N+1 Singer - Consort Medical - FY results in line with expectations; reiterate Buy

Today’s FY results are in line with our expectations, highlighting an improving operating performance at Aesica. The core Bespak delivered an in-line performance, impacted as expected by the termination of the supply agreement with Nicovations. We reiterate our Buy recommendation (upgraded from Hold in December 2016) and 1,125p target price.

Companies: Consort Medical

Consort Medical

Company Profile

  • Personnel
  • Jonathan Glenn, CEO
  • Chris Brinsmead, Chairman

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Consort Medical. We currently have 57 research reports from 5 professional analysts.

Latest News/RNS

(more news)
Date Source Announcement
02Mar20 13:50 RNS Total Voting Rights
20Feb20 07:15 RNS Despatch of formal compulsory acquisition notices
17Feb20 16:24 RNS Compulsory acquisition of Consort Shares
06Feb20 17:00 RNS Notice of Cancellation of Listing
06Feb20 16:31 RNS Director/PDMR Shareholding
06Feb20 13:30 RNS Holding(s) in Company
05Feb20 17:30 RNS Consort Medical
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Consort Medical

  • Providers covering

    Consort Medical

  • 17 May 22
Confidence in profitable expansion rebuilding

2021 was a tough year which saw the non-repeat of highly profitable hand sanitiser sales, almost no Chinese sales and the impact of input/cost inflation. However, it successfully integrated 2 acquisitions, which enhance the portfolio and earnings quality, and locked in the planned synergies. With new distribution agreements (inc to China), and mitigations in place to claw back lost margin, VLG looks set to return to profitable growth. The platform is highly scalable and trades on just 5x EV/EBIT

Companies: Venture Life Group Plc
  • 17 May 22
First clinical evidence for LBP in asthma

MRx-4DP0004 is 4D Pharma’s oral, immunomodulatory, single strain Live Biotherapeutic product (LBP). The safety portion of this Phase 1/2 (Part A) met the primary endpoint of safety and tolerability, with five secondary endpoints qualitatively improved over the placebo arm. The data is being presented in poster session at the ATS meeting May 15-18, 2022.

Companies: 4d Pharma PLC
  • 23 May 22
LIBERUM: Futura Medical* - A deal the market has been waiting for


Companies: Futura Medical plc
  • 17 May 22
Bugs as drugs...and vaccines

4D Pharma is a pharmaceutical company developing Live Biotherapeutic Products (LBPs), a novel class of drug derived from the human gut microbiome. This differentiated approach focuses on leveraging the interactions of LBPs with host biology, underpinned by a proprietary MicroRx® platform. This has generated a strong clinical and preclinical pipeline of single strain LBPs targeting major diseases across multiple therapeutic area. A well flagged cash requirement overshadows the stock but the exper

Companies: 4d Pharma PLC
  • 06 May 22
Morning Note – 6 May 2022


Companies: SDI Group plc
  • 20 May 22
Cenkos: Healthcare Sector - Ward Round

Weekly round-up of AIM-listed healthcare news. Venture Life Group, GENinCode, Kromek, Alliance Pharma, Polarean Imaging, Benchmark Holdings, Ondine Biomedical, Verici Dx, Faron Pharmaceuticals, Avacta Group, Abingdon Health, Open Orphan, Belluscura, Hutchmed (China), Oxford Biodynamics

Companies: ANIC RUA CREO GENI HEIQ IHC IXI IUG OPTI SBTX VAL VLG

  • 16 May 22
CMD demonstrated broader opportunity set

Yourgene’s Capital Markets Day on 26/4 provided a strong illustration of the significant strategic progress the group has made in recent years. The pandemic was both a blessing and a curse for YGEN, delaying some opportunities, but catalysing others and leaving the group in a stronger net position than where it started. The building blocks are now in place and, as healthcare markets normalise globally, we believe Yourgene is poised for a period of extended growth, with multiple opportunities to

Companies: Yourgene Health Plc
  • 16 May 22
Hybridan Small Cap Feast 16/05/22

Dish of the day Joiners: No Joiners Today. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Lekoil, the oil and gas exploration and production Company with a focus on Nigeria and West Africa intends to join the AQSE Growth Market. The Company was previously listed on AIM (LEK.L), however, Ordinary Shares have been suspended from trading on AIM since October 2021. Due 18th May 2022. EnSilica, intends to join AIM. EnSilica is a designer and supplier of mixed signal Application Specifi

Companies: EEE FARN FCAP HZM JLP NSCI SRE

  • 17 May 22
Cenkos: Venture Life Group Plc -- FY21 results, positive outlook

Venture Life Group has reported its results for FY21A, with revenues and adjusted EBITDA coming in ahead of our forecasts. Revenues, supported by two acquisitions, grew 9% to £32.8m with the acquisitions more than offsetting lost FY20A COVID-related sales and significantly reduced shipments to China. The gross margin was also affected by these factors, though also supported by higher margin acquisitions. Adjusted EBITDA grew 8%. Management have provided a positive outlook for FY22E, based on tra

Companies: Venture Life Group Plc
  • 19 May 22
SHORE CAPITAL - RUA Life Sciences - Cessation of coverage RYA, 42p - We are withdrawing our forecasts and ceasing research coverage


Companies: RUA Life Sciences Plc
  • 06 May 22
Omega Diagnostics - Placing raises £2.0m with Open Offer up to £2.0m

Omega Diagnostics has raised £2.0m, with up to £2.0m possible via an Open Offer to provide a bridge to the sale of the CD4 business and enable it to focus on the growth opportunities within its core business, Health & Nutrition. Having sold its Alva site in March for £1m, with a transitionary agreement put in place with Accubio until December 2022 to ensure the continued production of CD4 lateral flow tests, Omega has elected to sell the CD4 business, which would cost c.£1.5m to relocate to Ely

Companies: Omega Diagnostics Group PLC
  • 18 May 22
Hybridan Small Cap Feast 18/05/22

Dish of the day Joiners: Lekoil, the oil and gas exploration and production Company with a focus on Nigeria and West Africa has joined the Access Segment of the AQSE Growth Market. The Company was previously listed on AIM (LEK.L), however, Ordinary Shares have been suspended from trading on AIM since October 2021. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Psych Capital PLC, intends to list on the AQSE Growth Market. Psych operates the Psych Platform (a business-to-business ne

Companies: CZA AXL AEE CORA D4T4 EKF ORPH PWM PPH SYM

  • 19 May 22
Poised for multiple value inflection points

FY21 results were well-trailed and contain no surprises. The company continues to execute in line or ahead of plan and, following a £10m fundraise post-period end, is funded through a number of key inflection points. Investors can look forward to a number of these in the near term, including commercial launch and first revenues from first product Tuteva later this year. Rolling forward our risk-adjusted DCF results in a further increase in our TP to 76p (from 65p). we reiterate our Buy recommend

Companies: Verici Dx Plc
  • 23 May 22
Trinity Delta Lighthouse: Futura Medical

Trinity Delta view: The deal with Cooper for the commercially important EU (including UK) markets is a critical milestone that could be transformative for Futura Medical. The depth of due diligence suggests a strong commitment from Cooper, that should be sustained in the longer term given contractual marketing spend. We currently value Futura Medical at £264m, equivalent to 92p per share but expect to review this as visibility on expected launch timings increases and also when the results of the

Companies: Futura Medical plc
  • 19 May 22
Dowgate on Belluscura - Master Supply Agreement Fundraising. Forecasts and TP upgrade

Belluscura announced in March that it had signed a Master Supply Agreement with InnoMax to manufacture the X-PLO2R portable oxygen concentrator family of products in China which provides a platform to expand distribution into Asian markets while also significantly increasing manufacturing capacity and reducing per unit manufacturing costs.

Companies: Belluscura PLC